Why is Brawn Biotech falling/rising?

As of 01-Sep, Brawn Biotech Ltd's stock price is currently at 23.39, reflecting a slight decrease of 0.01, or 0.04%. Despite this minor decline, the stock has shown strong performance over the past week and month, with returns of 12.45% and 17.54%, respectively. However, today's performance indicates a reversal after eight consecutive days of gains, and the stock has underperformed its sector by 2.56%. While it is trading above all key moving averages, the company's long-term fundamentals are concerning, with a weak Return on Equity (ROE) of 0% and negative growth in net sales and operating profit over the last five years. Additionally, the stock's risk is heightened due to negative EBITDA and a poor ability to service its debt. In the broader market context, Brawn Biotech's recent performance contrasts sharply with the benchmark, as the Sensex has declined by 1.56% over the past week and 0.29% over the past month. Although the stock has outperformed the market over the past year with a return of 12.72% compared to the Sensex's decline of 2.43%, the overall market has been under pressure, which may contribute to investor caution. The significant increase in delivery volume suggests rising investor participation, yet the stock's recent price movement and weak long-term fundamentals indicate a complex situation that may lead to further scrutiny from investors.